Stealth BioTherapeutics Announces First Patient Enrolled in Global Phase 3 Clinical Program for Elamipretide in Patients with Dry Age-Related Macular Degeneration Uncategorized / June 5, 2024April 14, 2025
Stealth BioTherapeutics’ Barth Syndrome NDA Receives Priority Review Designation Press Release / May 7, 2024April 14, 2025
Stealth BioTherapeutics to Present at JMP Citizens Life Sciences Conference Press Release / May 6, 2024April 14, 2025
Stealth BioTherapeutics Announces Participation at Upcoming OIS, ARVO, & RWC Conferences Press Release / May 1, 2024April 14, 2025
Stealth Biotherapeutics Announces FDA Acceptance of New Drug Application for Elamipretide for the Treatment of Barth Syndrome Press Release / April 8, 2024April 14, 2025
Stealth BioTherapeutics Presents Data of Novel Compound, SBT-589, in Friedreich’s Ataxia Cardiac Models at the Wellcome Trust Mitochondrial Medicine Conference Press Release / March 19, 2024April 14, 2025
Stealth BioTherapeutics to Present at the Baird 2023 Biotech Discovery Series Press Release / December 4, 2023April 14, 2025
Stealth BioTherapeutics to Present at the 2023 Ophthalmology Innovation Source Summit Press Release / November 28, 2023April 14, 2025
Stealth BioTherapeutics Completes Target Enrollment in Global Phase 3 NuPOWER Trial in Patients with Primary Mitochondrial Myopathy Press Release / September 11, 2023April 14, 2025
Stealth BioTherapeutics Awarded Grant from The Michael J. Fox Foundation to Support Development of SBT-272 in Parkinson’s Disease Press Release / August 9, 2023April 14, 2025
